Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 11/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.52 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431945 | 1.00 | CTSB (0.55) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7400099 | 0.89 | REN (0.49) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8568989 | 0.86 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8564599 | 0.83 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6443651 | 0.83 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6443658 | 0.83 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7329015 | 0.83 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5394908 | 0.83 | MMP1 (0.44) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5401492 | 0.82 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5872214 | 0.81 | LAP3 (0.48) | CTSBPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | G.D. Searle & Co. (now G.D. Searle, LLC) (US) | 2007-01-18 | — | — | US | disclosed |
| EP-0813868-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-0558603-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0558630-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0815856-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0813867-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0813868-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5622949-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620977-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5610190-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5475013-A | Inhibit human immunodeficiency virus protease | MONSANTO COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1993023368-A1 | UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | TMPRSS15, TMPRSS11D, MME | CTSB 78/4885PSEN1 647/4885PSEN2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.